Azithromycin Use in Clinical Practice

Respiratory Tract Infections

The American Thoracic Society recommends azithromycin as first-line monotherapy for previously healthy outpatients with community-acquired pneumonia (CAP) without comorbidities or recent antibiotic use, particularly effective against atypical pathogens like Mycoplasma pneumoniae and Chlamydia pneumoniae 1, 2
For hospitalized non-ICU patients with CAP, azithromycin can be used in combination with a β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) 1
The Infectious Diseases Society of America recommends combining azithromycin with a β-lactam for ICU patients with CAP to ensure coverage for both S. pneumoniae and Legionella species 1
Azithromycin is indicated for treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) due to H. influenzae, M. catarrhalis, or S. pneumoniae, and can be considered as long-term therapy (≥2 months) for patients with bronchiectasis who have had ≥3 exacerbations in the previous 12 months 3, 4

The Centers for Disease Control and Prevention (CDC) recommends azithromycin as the preferred macrolide during pregnancy when treatment is necessary, as it is safer than clarithromycin, which has shown increased risk for spontaneous abortion in some studies 5
Azithromycin can be used for bacterial respiratory infections in HIV-infected patients 5

The Infectious Diseases Society of America recommends against using azithromycin as monotherapy in areas with high rates (>25%) of macrolide-resistant S. pneumoniae 2, 7
Azithromycin should not be used in patients with known or suspected non-tuberculous mycobacteria (NTM) infection, and prior to initiating long-term macrolide therapy, patients should be screened for NTM infection 8

For long-term therapy in bronchiectasis, azithromycin can be dosed at 500mg three times weekly or 250mg daily 3

Failing to consider local resistance patterns before prescribing azithromycin monotherapy for respiratory infections can lead to treatment failure, as recommended by the Infectious Diseases Society of America 1, 2
Using azithromycin for severe pneumonia requiring hospitalization when combination therapy is indicated can result in poor outcomes, as recommended by the American Thoracic Society 1
Not screening for NTM before starting long-term macrolide therapy can lead to unnecessary treatment and potential harm, as recommended by the British Thoracic Society 8